Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FTC/Industry Showdown Over Orange Book Patent Listings Could Come In 2024

Jan 05 2024

• By Brenda Sandburg

ftc orange book patents — Battles over Orange Book patent listings seem likely as companies reject FTC claims of improper listings. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Related Content

Possible Orange Book Revisions Back In Play With US FDA Report To Congress

Feb 24 2022

FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes

Jan 27 2023

In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap

Nov 08 2023

FDA’s Orange Book Dispute Resolution Process May Grow Teeth With FTC Patent Listing Challenges

Nov 28 2023

FTC Campaign Against Orange Book Patent Listings Extends To Mylan’s Battle With Sanofi

Nov 21 2023

FTC’s Rahul Rao On Why Agency Targeted Drug-Device Orange Book Patents

Nov 13 2023

Related Companies

Amneal Pharmaceuticals, Inc.

Teva Pharmaceuticals USA Inc.

Forest Laboratories

Viatris Inc.

Boehringer Ingelheim GmbH

Novo Nordisk A/S

Additional Topics

United States Generic Drugs Intellectual Property Legal Issues Enforcement Market Access Policy Pink Sheet Perspectives Combination Products BioPharmaceutical Medical Device

More from Pink Sheet Perspectives

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window